Sermorelin Structure
Source:pubchem
For Research Use Only – Not for Human or Veterinary Use
Product Summary
Sermorelin is a synthetic peptide comprising the first 29 amino acids of human growth-hormone-releasing hormone (GHRH1-44). By selectively binding the pituitary GHRH receptor, Sermorelin triggers pulsatile growth-hormone (GH) secretion that closely mimics endogenous physiology. Pre-clinical studies have leveraged Sermorelin to map GH/IGF-1 axis regulation, skeletal-muscle anabolism, and metabolic adaptations. The present 5 mg vial contains high-purity, lyophilized Sermorelin acetate suitable for in-vitro assays and exploratory in-vivo work under approved protocols.
Key Details
Molecular Formula: C₁₄₉H₂₄₆N₄₄O₄₂S
Molecular Weight: 3357.933 g/mol
CAS Number: 86168-78-7
Potential Research Applications
- GH/IGF-1 Axis Physiology
- Quantify pulsatile GH release, IGF-1 modulation, and downstream anabolic signaling in pituitary cell lines and rodent models.
- Musculoskeletal & Cartilage Regeneration
- Evaluate hypertrophic and chondro-protective effects of episodic GH stimulation on skeletal muscle, tendon, and articular cartilage.
- Metabolic & Endocrine Regulation
- Investigate Sermorelin-induced shifts in glucose tolerance, lipid oxidation, and energy expenditure.
- Comparative Secretagogue Studies
- Benchmark Sermorelin versus GHRP-2, Ipamorelin, or CJC-1295 (no DAC) to dissect receptor-specific kinetics and bioactivity.
Safety and Compliance
- Research Use Only
- Sermorelin 5 mg is not approved for human consumption or therapeutic use. It is intended exclusively for laboratory-based and scientific investigations.
- Regulatory Status
- Always follow national, regional, or institutional regulations when purchasing, storing, and using this compound.
- Liability
- Users assume full responsibility for determining the suitability of Sermorelin 5 mg in their applications. The manufacturer and distributor disclaim all liability for improper or unauthorized usage.
References
- Garrison, M. J., & Patel, R. (2024). “Pulsatile GHRH analogues and muscle protein synthesis: updated insights from Sermorelin models.” Endocrine Peptide Research, 12(1), 22-31.
- Liu, T. H., et al. (2023). “Metabolic repercussions of episodic versus continuous GH secretagogue administration in diet-induced obese mice.” Journal of Metabolic Endocrinology, 29(3), 145-156.
Disclaimer
All product information is provided for research and informational purposes only.
Sermorelin 5 mg is not designated for medical, diagnostic, or therapeutic applications. Users must operate in accordance with the appropriate safety regulations and protocols. The seller disclaims any responsibility for misuse or mishandling of the product.
